<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18417837</article-id><article-id pub-id-type="pmc">2636114</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_255_40375</article-id><article-id pub-id-type="pmid">18417837 </article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Debate on the various anti-vascular endothelial growth factor drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khalili</surname><given-names>Mohammad Reza</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hosseini</surname><given-names>Hamid</given-names></name><degrees>MD</degrees></contrib></contrib-group><aff>Shiraz University of Medical Sciences, Department ofOphthalmology, Poostchi Eye Research Center, Iran.</aff><author-notes><corresp id="cor1">Correspondence to Dr. Hamid Hosseini, Shiraz University ofMedical Sciences, Department of Ophthalmology,Poostchi Eye Research Center, Iran. Email: <email>hosseinih@sums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><volume>56</volume><issue>3</issue><fpage>255</fpage><lpage>256</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>We read with interest the article &#x02033;A comparative debate onthe various anti-vascular endothelial growth factor drugs:Pegaptanib sodium (Macugen), ranibizumab (Lucentis) andbevacizumab (Avastin)&#x02033; by Nagpal <italic>et al</italic>.<xref ref-type="bibr" rid="ref1">1</xref></p><p>Herein, we demonstrate another potentially useful aspectof pegaptanib sodium in comparison with ranibizumab andbevacizumab, not mentioned in the above article.</p><p>Vascular endothelial growth factor-A (VEGF-A) has beenrecognized as an important neuroprotectant in the central nervoussystem.<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref> Receptors for VEGF-A are also present innormal retinal neuronal cells,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref> indicating a possiblefunctional role for VEGF-A in the neural retina. Recently, Nishijama <italic>et al</italic>. demonstrated thatVEGF-A is a survival factor for retinal neurons and a criticalneuroprotectant during the adaptive response to ischemic injury.<xref ref-type="bibr" rid="ref6">6</xref>Perhaps, the most surprising finding in their study concerned thereliance of normal retinal ganglion cells (RGCs) on VEGF-A forsurvival. Through both direct quantification of RGC numbers andassessment of optic nerve axon viability, they observed a dose-dependent decrease in neuron numbers after VEGF depletionwith an antibody that blocks all VEGF isoforms. Interestingly,when the effects of VEGF were blocked with pegaptanib, whichbinds to VEGF164 and does not bind to VEGF120, there was nodecrease in retinal RGC viability. VEGF164-treated eyes afterischemia showed obvious signs of disseminated intraretinalhemorrhages, suggesting an increase in vascular leakage causedby the VEGF164 treatment whereas no retinal hemorrhage wasdetected in the VEGF120-treated eyes.<xref ref-type="bibr" rid="ref6">6</xref> To conclude, the use ofselective anti-VEGF agents such as pegaptanib, which inhibitspathologic VEGF164 and spares all other VEGF isomers, isstrongly recommended to preserve retinal neurons in the longterm, especially in the context of ischemic retinal diseases.</p></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>M</given-names></name><name><surname>Nagpal</surname><given-names>K</given-names></name><name><surname>Nagpal</surname><given-names>PN</given-names></name></person-group><article-title>A comparative debate on thevarious anti-vascular endothelial growth factor drugs: Pegaptanibsodium (Macugen), ranibizumab (Lucentis) and bevacizumab(Avastin)</article-title><source>Indian J Ophthalmol</source><year>2007</year><volume>55</volume><fpage>437</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17951900</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storkebaum</surname><given-names>E</given-names></name><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><article-title>VEGF: Once regardedas a specific angiogenic factor, now implicated in neuroprotection</article-title><source>Bioessays</source><year>2004</year><volume>26</volume><fpage>943</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15351965</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Childs</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>XO</given-names></name><name><surname>Logvinova</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name></person-group><article-title>VEGF-induced neuroprotection, neurogenesis and angiogenesisafter focal cerebral ischemia</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>1843</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12813020</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Ryan</surname><given-names>AM</given-names></name><name><surname>Rohan</surname><given-names>R</given-names></name><name><surname>Amano</surname><given-names>S</given-names></name><name><surname>Agular</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Constitutive expression of VEGF, VEGFR-1 and VEGFR-2 in normaleyes</article-title><source>Invest Ophthalmol Vis Sci</source><year>1999</year><volume>40</volume><fpage>2115</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10440268</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Cepko</surname><given-names>CL</given-names></name></person-group><article-title>Flk-1, a receptor for vascular endothelial growthfactor (VEGF), is expressed by retinal progenitor cells</article-title><source>J Neurosci</source><year>1996</year><volume>16</volume><fpage>6089</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">8815891</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>YS</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Schubert</surname><given-names>W</given-names></name><name><surname>Jo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor: A is a survival factor forretinal neurons and a critical neuroprotectant during the adaptiveresponse to ischemic injury</article-title><source>Am J Pathol</source><year>2007</year><volume>171</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17591953</pub-id></element-citation></ref></ref-list></back></article>